News

April 28, 2025

AffyImmune Announces Plenary Oral Presentation on ICAM-1 Directed CAR T Therapy AIC100 at AACR 2025

November 25, 2024

AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer

September 23, 2024

AffyImmune Appoints Drs. Rick Rutter and Jorge Nieva to Board of Directors

July 23, 2024

AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer

July 15, 2024

AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer

May 23, 2024

AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer